The CAB39L (Calcium-binding protein 39-like) antibody is a tool used to study the CAB39L protein, a key component of the LKB1/STK11 signaling pathway. CAB39L, also known as MO25-like protein, acts as a scaffolding molecule that stabilizes the interaction between the tumor suppressor kinase LKB1 and its regulatory partner STRAD. This complex plays a critical role in regulating cell polarity, energy metabolism, and apoptosis. Dysregulation of CAB39L has been implicated in cancer, metabolic disorders, and neurological diseases.
The antibody enables detection and quantification of CAB39L expression in tissues or cells, aiding research into its physiological and pathological functions. It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Studies using CAB39L antibodies have revealed its dual role as both an oncogene and tumor suppressor, depending on cellular context. Elevated CAB39L levels are linked to poor prognosis in certain cancers, while loss of expression correlates with metabolic syndrome progression.
Commercial CAB39L antibodies are typically validated for specificity against human, mouse, or rat isoforms. Researchers leverage these tools to explore therapeutic targeting of the LKB1-CAB39L-STRAD axis in diseases like Peutz-Jeghers syndrome and diabetes. Ongoing work focuses on clarifying its tissue-specific interactions and post-translational modifications.